NCT05591755View on ClinicalTrials.gov

Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis

PHASE3CompletedINTERVENTIONAL
Enrollment

229

Participants

Timeline

Start Date

November 18, 2022

Primary Completion Date

August 9, 2023

Study Completion Date

August 9, 2023

Conditions
Seasonal Allergic Conjunctivitis
Interventions
DRUG

Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution

Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution

DRUG

Ketotifen fumarate ophthalmic solution 0.035%

Ketotifen fumarate ophthalmic solution 0.035%

DRUG

Brimonidine tartrate ophthalmic solution 0.025%

Brimonidine tartrate ophthalmic solution 0.025%

DRUG

Experimental: Vehicle ophthalmic solution

Experimental: Vehicle ophthalmic solution

Trial Locations (6)

22046

108 Emerson Clinical Research Institute Inc., Falls Church

23230

107 Virginia Eye Institute, Richmond

37072

105 - Advancing Vision Research, Goodlettsville

38119

102 Total Eye Care, PA, Memphis

40206

104 Butchertown Clinical Trials, Louisville

01810

101 Andover Eye Associates, Andover

All Listed Sponsors
lead

Bausch & Lomb Incorporated

INDUSTRY